10-QPeriod: Q2 FY2002

QUEST DIAGNOSTICS INC Quarterly Report for Q2 Ended Jun 30, 2002

Filed August 13, 2002For Securities:DGX

Summary

Quest Diagnostics Incorporated (DGX) reported strong financial performance for the quarter and six months ended June 30, 2002. Net revenues increased significantly, driven by a combination of higher testing volumes and improved average revenue per requisition. This growth was substantially bolstered by the acquisition of American Medical Laboratories, Inc. (AML) on April 1, 2002, which added scale and expanded the company's operational footprint. The company also continued to benefit from its ongoing Six Sigma and Standardization initiatives, leading to improved efficiencies and cost management, which contributed to higher profitability. Management highlights the successful integration efforts and the positive impact of recent acquisitions on revenue and market position. Despite investments in IT strategy and growth opportunities, the company demonstrated a strong increase in net income and EBITDA compared to the prior year, even after accounting for the impact of new accounting standards like SFAS 142, which removed goodwill amortization. Looking ahead, Quest Diagnostics remains focused on strategic growth, including the pending acquisition of Unilab Corporation, and expects continued operational improvements.

Key Highlights

  • 1Net revenues increased by 14.7% for the quarter and 11.1% for the six months ended June 30, 2002, compared to the prior year.
  • 2The acquisition of American Medical Laboratories, Inc. (AML) on April 1, 2002, was a significant contributor to revenue growth, accounting for approximately 60% of the three-month increase and 40% of the six-month increase.
  • 3Clinical testing volume (requisitions) increased by 12% for the quarter and 7.3% for the six months, while average revenue per requisition grew by 2.4% and 3.2% respectively.
  • 4Net income for the six months ended June 30, 2002, more than doubled to $153.8 million from $61.2 million in the prior year, excluding extraordinary items and the impact of SFAS 142 in 2001.
  • 5EBITDA showed robust growth, increasing to $195 million (18.2% of net revenues) for the quarter and $350 million (17.4% of net revenues) for the six months, up from $149 million (16.0%) and $271 million (15.0%) respectively in the prior year.
  • 6The company is actively pursuing strategic growth, evidenced by the acquisition of AML and the pending acquisition of Unilab Corporation, subject to regulatory approval.
  • 7Selling, general, and administrative expenses as a percentage of net revenues decreased, reflecting improved efficiencies, particularly in bad debt expense, which fell to 5.2% of net revenues for the quarter from 6.0% year-over-year.

Frequently Asked Questions

The acquisition of AML, completed on April 1, 2002, was a primary driver of Quest Diagnostics' revenue growth. It contributed significantly to the increase in net revenues, testing volumes, and expanded the company's operational footprint. While integration costs are expected, the acquisition is positioned to enhance the company's market position.

Effective January 1, 2002, Quest Diagnostics adopted SFAS 142, which eliminated the amortization of goodwill. This change has resulted in a significant increase in reported net income compared to prior periods when goodwill amortization was expensed. The company provides adjusted figures in its financial statements to show results as if SFAS 142 had been in effect for all periods presented.

Quest Diagnostics entered into a definitive agreement to acquire Unilab Corporation on April 2, 2002. The transaction is subject to customary closing conditions, including regulatory review by the FTC, which has issued a 'second request' for information. The company anticipates closing in the third quarter of 2002, subject to these conditions. If completed, the acquisition will further expand Quest Diagnostics' operations, particularly in California, and is expected to be financed through a combination of debt and cash on hand. Integration costs are estimated to be up to $20 million.

Quest Diagnostics has implemented Six Sigma and Standardization initiatives to drive efficiencies, which have helped manage costs. Selling, general, and administrative expenses as a percentage of net revenues decreased due to these efficiencies, notably in bad debt expense. While the company is making investments in IT and strategic growth, and absorbing the cost structure of newly acquired entities like AML, overall cost management remains a focus.